Notícias

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05% move from the preceding trading day.

GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.

Drug companies have found promising new options for one of the most aggressive and hardest-to-treat forms of breast cancer after decades with few breakthroughs. Gilead Sciences won Food and Drug Administration approval Wednesday to sell its drug Trodelvy as a first treatment for newly diagnosed patients with the advanced form of a type of breast cancer known as “triple negative” because it has characteristics that render common treatments ineffective. It is the second such approval in about a month: AstraZeneca and Daiichi Sankyo rival drug, Datroway, was approved for a similar group of patients in May.

By Daniella Parra VERAXA Biotech AG (Nasdaq: VRXA)has expanded its R&D facility in Heidelberg, Germany, increasing laboratory space by more than 60% to support team growth and accelerate its cancer therapy programs toward clinical development, the company said. The expansion strengthens research capabilities while allowing the company to remain in Heidelberg’s leading medical oncology hub […] The post VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development a

Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep premium for its next act.

The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innovate and expand, setting themselves up for long-term success.

By Karen Roman Prolium Bioscience, Inc. said it dosed its first patient in Phase 1/2 study of PRO-203, a T-cell engager treatment for systemic sclerosis, following the completion of a study in 20 healthy volunteers. The company also completed the last patient and visit in a 26-week study of PRO-203 in treatment-refractory lupus nephritis patients, […] The post Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing appeared first on ExecEdge.

With a short percentage of shares outstanding of 2.07%, Gilead Sciences, Inc. (NASDAQ:GILD) is among the 7 Best Longevity and Anti-Aging Stocks to Buy. On June 15, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application for Yeztugo 300-mg tablets as a potential once-weekly oral pre-exposure prophylaxis (PrEP) treatment for HIV prevention. […]

Merck (NYSE:MRK) received FDA approval for expanded use of KEYTRUDA and KEYTRUDA QLEX with WELIREG as adjuvant treatment in certain renal cell carcinoma patients. The FDA also granted expanded approval for CAPVAXIVE in children and adolescents at higher risk for pneumococcal disease, making it the only PCV indicated for this US group. Merck and Gilead reported positive Phase 3 data for a once weekly oral HIV treatment regimen. Separately, Merck discontinued a Phase 3 lung cancer trial...

By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for its platform at the BIO International Convention in San Diego, California, taking place on June 22-25, 2026, it stated […] The post VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 appeared first on ExecEdge.

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Since December 2025, Gilead Sciences has been in a holding pattern, posting a small return of 2.7% while floating around $124.73. The stock also fell short of the S&P 500’s 10.9% gain during that period.

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now. On June 12, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts for the current outbreak of Ebola Bundibugyo virus […]

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening its HIV portfolio.

Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.

Gilead Sciences (GILD) reached $124.3 at the closing of the latest trading day, reflecting a -1.03% change compared to its last close.

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the Top 10 Income Stocks with the Highest Upside Potential. On May 22, Reuters reported that Gilead Sciences, Inc. (NASDAQ:GILD) said its experimental drug for a rare and potentially fatal liver infection had received US approval. The U.S. Food and Drug Administration approved Hepcludex for the treatment of […]

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 IDEAL trial results for Livdelzi in primary biliary cholangitis (PBC), supporting alkaline phosphatase (ALP) normalization as a treatment goal. The US Food and Drug Administration granted accelerated approval for Livdelzi in PBC. The FDA also approved Hepcludex for the treatment of hepatitis delta virus infection. Gilead Sciences, known for its focus on antiviral and liver disease treatments, is adding fresh momentum to its liver...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to invest in. On June 2, Gilead Sciences announced positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in patients with primary biliary cholangitis/PBC. The study showed statistically significant improvements in composite alkaline phosphatase/ALP normalization compared with placebo after 52 weeks. The trial […]

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 7 Best Longevity Stocks to Buy Now. On June 5, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) applauded the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. CEO Daniel O’Day said South Africa is “at the heart of global […]

Gilead Sciences Inc. (NASDAQ:GILD) is one of the top large cap value stocks to buy now. On June 8, Gilead Sciences and Merck announced positive topline results from two Phase 3 clinical trials, ISLEND-1 and ISLEND-2, evaluating their investigational once-weekly oral HIV treatment. The regimen, which combines islatravir and lenacapavir, successfully met its primary efficacy […]

Gilead Sciences, Inc. (NASDAQ:GILD) is a deep value stock to invest in now. On June 2, Gilead Sciences, Inc. (NASDAQ:GILD) announced topline results of the Phase 3 IDEAL study for its candidate drug Livdelzi in people with primary biliary cholangitis (PBC). Study results showed that treatment with Livdelzi (seladelpar) led to significantly more patients achieving […]

Gilead's HIV franchise gains momentum as Biktarvy and Descovy drive growth, Yeztugo outlook rises, and late-stage pipeline advances.

Cencora (NYSE:COR) has entered a major U.S. distribution partnership with Kite Pharma, a Gilead company. The agreement focuses on market access and distribution support for FDA approved CAR T cell therapies across U.S. treatment centers. The collaboration is aimed at easing logistical and administrative hurdles for healthcare providers using these personalized cancer treatments. Cencora comes into this Kite agreement with a mixed share price record. The stock is trading at $279.57, with...

Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.

Gilead Sciences (NasdaqGS:GILD) and Merck reported that their once weekly oral HIV regimen, islatravir and lenacapavir, met its primary endpoint in a Phase 3 trial, showing statistically non inferior efficacy to daily standard of care. The companies also stopped a Phase 3 study combining Trodelvy and KEYTRUDA in advanced lung cancer after the treatment did not deliver a statistically significant improvement in progression free survival. These mixed trial outcomes arrive with Gilead Sciences...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26 ) are up +0.76%, and June E-mini Nasdaq futures...